Special Considerations in Estate Planning for Same-Sex and Unmarried Couples

Sub-Nyquist sampling makes use of sparsities in analog signals to sample them at a rate lower than the Nyquist rate. The reduction in sampling rate, however, comes at the cost of additional digital signal processing (DSP) which is required to reconstruct the uniformly sampled sequence at the output of the sub-Nyquist sampling analog-to-digital converter. At present, this additional processing is computationally intensive and time consuming and offsets the gains obtained from the reduced sampling rate. This paper focuses on sparse multi-band signals where the user band locations can change from time to time and the reconstructor requires real-time redesign. We propose a technique that can reduce the computational complexity of the reconstructor. At the same time, the proposed scheme simplifies the online reconfigurability of the reconstructor

Mechanikal Applications of the Harmless Error Rule in Cases of Prosecutorial Grand Jury Misconduct

Even though time-interleaved analog-to-digital converters (ADCs) help to achieve higher bandwidth with simpler individual ADCs, gain, offset, and time-skew mismatch between the channels degrade the achievable resolution. Of particular interest is the time-skew error between channels which results in nonuniform samples and thereby introducing distortion tones at the output of the time-interleaved ADC. Time-varying digital reconstructors can be used to correct the time-skew errors between the channels in a time-interleaved ADC. However, the complexity of such reconstructors increases as their bandwidth approaches the Nyquist band. In addition to this, the reconstructor needs to be redesigned online every time the time-skew error varies. Design methods that result in minimum reconstructor order require expensive online redesign while those methods that simplify online redesign result in higher reconstructor complexity. This paper proposes a technique that can be used to simplify the online redesign and achieve a low complexity reconstructor at the same time

A 2-MS/s, 11.22 ENOB, extended input range SAR ADC with improved DNL and offset calculation

A 12-bit successive approximation register analog-to-digital converter (ADC) with extended input range is presented. Employing an input sampling scaling technique, the presented ADC can digitize the signals with an input range of 3.2 V pp-d (±1.33 V REF ). The circuit also includes a comparator offset compensation technique that results in a residual offset of less than 0.5 LSB. The chip has been designed and implemented in a 0.13-μm CMOS process and demonstrates the state-of-the-art performance, featuring an SNDR of 69.3 dB and the SFDR of 79 dB without requiring any calibration. Total power consumption of the ADC is 0.9 mW, with a measured differential non-linearity of 1.2/-1.0 LSB and INL of 2.3/-2.2 LSB

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Signal Reconstruction Algorithms for Time-Interleaved ADCs

An analog-to-digital converter (ADC) is a key component in many electronic systems. It is used to convert analog signals to the equivalent digital form. The conversion involves sampling which is the process of converting a continuous-time signal to a sequence of discrete-time samples, and quantization in which each sampled value is represented using a finite number of bits. The sampling rate and the effective resolution (number of bits) are two key ADC performance metrics. Today, ADCs form a major bottleneck in many applications like communication systems since it is difficult to simultaneously achieve high sampling rate and high resolution. Among the various ADC architectures, the time-interleaved analog-to-digital converter (TI-ADC) has emerged as a popular choice for achieving very high sampling rates and resolutions. At the principle level, by interleaving the outputs of M identical channel ADCs, a TI-ADC could achieve the same resolution as that of a channel ADC but with M times higher bandwidth. However, in practice, mismatches between the channel ADCs result in a nonuniformly sampled signal at the output of a TI-ADC which reduces the achievable resolution. Often, in TIADC implementations, digital reconstructors are used to recover the uniform-grid samples from the nonuniformly sampled signal at the output of the TI-ADC. Since such reconstructors operate at the TI-ADC output rate, reducing the number of computations required per corrected output sample helps to reduce the power consumed by the TI-ADC. Also, as the mismatch parameters change occasionally, the reconstructor should support online reconfiguration with minimal or no redesign. Further, it is advantageous to have reconstruction schemes that require fewer coefficient updates during reconfiguration. In this thesis, we focus on reducing the design and implementation complexities of nonrecursive finite-length impulse response (FIR) reconstructors. We propose efficient reconstruction schemes for three classes of nonuniformly sampled signals that can occur at the output of TI-ADCs. Firstly, we consider a class of nonuniformly sampled signals that occur as a result of static timing mismatch errors or due to channel mismatches in TI-ADCs. For this type of nonuniformly sampled signals, we propose three reconstructors which utilize a two-rate approach to derive the corresponding single-rate structure. The two-rate based reconstructors move part of the complexity to a symmetric filter and also simplifies the reconstruction problem. The complexity reduction stems from the fact that half of the impulse response coefficients of the symmetric filter are equal to zero and that, compared to the original reconstruction problem, the simplified problem requires only a simpler reconstructor. Next, we consider the class of nonuniformly sampled signals that occur when a TI-ADC is used for sub-Nyquist cyclic nonuniform sampling (CNUS) of sparse multi-band signals. Sub-Nyquist sampling utilizes the sparsities in the analog signal to sample the signal at a lower rate. However, the reduced sampling rate comes at the cost of additional digital signal processing that is needed to reconstruct the uniform-grid sequence from the sub-Nyquist sampled sequence obtained via CNUS. The existing reconstruction scheme is computationally intensive and time consuming and offsets the gains obtained from the reduced sampling rate. Also, in applications where the band locations of the sparse multi-band signal can change from time to time, the reconstructor should support online reconfigurability. Here, we propose a reconstruction scheme that reduces the computational complexity of the reconstructor and at the same time, simplifies the online reconfigurability of the reconstructor. Finally, we consider a class of nonuniformly sampled signals which occur at the output of TI-ADCs that use some of the input sampling instants for sampling a known calibration signal. The samples corresponding to the calibration signal are used for estimating the channel mismatch parameters. In such TI-ADCs, nonuniform sampling is due to the mismatches between the channel ADCs and due to the missing input samples corresponding to the sampling instants reserved for the calibration signal. We propose three reconstruction schemes for such nonuniformly sampled signals and show using design examples that, compared to a previous solution, the proposed schemes require substantially lower computational complexity

Low-complexity two-rate based multivariate impulse response reconstructor for time-skew error correction in m-channel time-interleaved ADCs

Nonuniform sampling occurs in time-interleaved analog-to-digital converters (TI-ADC) due to timing mismatches between the individual channel analog-to-digital converters (ADCs). Such nonuniformly sampled output will degrade the achievable resolution in a TI-ADC. To restore the degraded performance, digital time-varying reconstructors can be used at the output of the TI-ADC, which in principle, converts the nonuniformly sampled output sequence to a uniformly sampled output. As the bandwidth of these reconstructors increases, their complexity also increases rapidly. Also, since the timing errors change occasionally, it is important to have a reconstructor architecture that requires fewer coefficient updates when the value of the timing error changes. Multivariate polynomial impulse response reconstructor is an attractive option for an M-channel reconstructor. If the channel timing error varies within a certain limit, these reconstructors do not need any online redesign of their impulse response coefficients. This paper proposes a technique that can be applied to multivariate polynomial impulse response reconstructors in order to further reduce the number of fixed-coefficient multipliers, and thereby reduce the implementation complexity

Efficient signal reconstruction scheme for time-interleaved ADCs

Time-interleaved analog-to-digital converters (ADCs) exhibit offset, gain, and time-skew errors due to channel mismatches. The time skews give rise to a nonuniformly sampled signal instead of the desired uniformly sampled signal. This introduces the need for a digital signal reconstructor that takes the "nonuniform samples" and generates the "uniform samples". In the general case, the time skews are frequency dependent, in which case a generalization of nonuniform sampling applies. When the bandwidth of a digital reconstructor approaches the whole Nyquist band, the computational complexity may become prohibitive. This paper introduces a new scheme with reduced complexity. The idea stems from recent multirate-based efficient realizations of linear and time-invariant systems. However, a time-interleaved ADC (without correction) is a time-varying system which means that these multirate-based techniques cannot be used straightforwardly but need to be appropriately analyzed and extended for this context